Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Armata Pharmaceuticals (ARMP) Free Cash Flow (2016 - 2018)

Armata Pharmaceuticals (ARMP) has disclosed Free Cash Flow for 6 consecutive years, with -$3.6 million as the latest value for Q4 2018.

  • Quarterly Free Cash Flow fell 50.23% to -$3.6 million in Q4 2018 from the year-ago period, while the trailing twelve-month figure was -$11.2 million through Dec 2018, down 20.79% year-over-year, with the annual reading at -$26.3 million for FY2025, 33.29% up from the prior year.
  • Free Cash Flow hit -$3.6 million in Q4 2018 for Armata Pharmaceuticals, down from -$2.2 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$626000.0 in Q3 2017 to a low of -$3.9 million in Q1 2014.
  • Historically, Free Cash Flow has averaged -$2.8 million across 5 years, with a median of -$2.8 million in 2014.
  • Biggest five-year swings in Free Cash Flow: plummeted 250.31% in 2014 and later soared 80.19% in 2017.
  • Year by year, Free Cash Flow stood at -$3.2 million in 2014, then rose by 26.15% to -$2.4 million in 2015, then surged by 36.16% to -$1.5 million in 2016, then tumbled by 57.97% to -$2.4 million in 2017, then crashed by 50.23% to -$3.6 million in 2018.
  • Business Quant data shows Free Cash Flow for ARMP at -$3.6 million in Q4 2018, -$2.2 million in Q3 2018, and -$1.9 million in Q2 2018.